Diabetologia

, Volume 34, Issue 1, pp 52–54

Basal and stimulated plasma levels of pancreatic amylin indicate its co-secretion with insulin in humans

  • E. Hartter
  • T. Svoboda
  • B. Ludvik
  • M. Schuller
  • B. Lell
  • E. Kuenburg
  • M. Brunnbauer
  • W. Woloszczuk
  • R. Prager
Rapid Communications

DOI: 10.1007/BF00404025

Cite this article as:
Hartter, E., Svoboda, T., Ludvik, B. et al. Diabetologia (1991) 34: 52. doi:10.1007/BF00404025

Summary

Amylin is a 37-amino acid pancreatic polypeptide, probably involved in the pathophysiology of Type 2 (non-insulin-dependent) diabetes mellitus. We have determined amylin in human plasma by extraction-based radioimmunoassay (Sep-Pak C18). Of 23 healthy control subjects plasma amylin was determined as 11.9+-3.5 ng/l. Of 27 patients with Type 2 diabetes receiving insulin the amylin levels were lower, and in 16 patients with Type 2 diabetes on oral medication they were higher than in the control subjects: 8.2+-4.4 ng/l (p<0.01) vs 18.8+-9.9 ng/l (p<0.05). In 14 Type 1 (insulin-dependent) diabetic patients we found extremely low mean amounts of amylin: 2.9+-1.9 ng/l (p<0.002). Thus, basal amylin appears to be associated with the capacity to release insulin. An oral glucose load stimulated the release of amylin, this was more pronounced in patients with Type 2 diabetes than in healthy subjects. An excellent correlation of mean amylin with mean insulin concentrations was obtained (r=0.949). In patients with Type 2 diabetes amylin was reduced congruent to a decrease in C-peptide during a hyperinsulinaemic, euglycaemic glucose clamp experiment (r=0.971 for linear correlation between C-peptide levels and amylin). We conclude, that amylin and insulin are co-secreted in humans, and that the amylin release is under feedback-control by insulin.

Key words

Amylin diabetes associated polypeptide islet amyloid polypeptide 

Copyright information

© Springer-Verlag 1991

Authors and Affiliations

  • E. Hartter
    • 1
  • T. Svoboda
    • 1
  • B. Ludvik
    • 1
  • M. Schuller
    • 1
  • B. Lell
    • 1
  • E. Kuenburg
    • 1
  • M. Brunnbauer
    • 1
  • W. Woloszczuk
    • 2
  • R. Prager
    • 1
  1. 1.Second Department of Internal MedicineUniversity of ViennaViennaAustria
  2. 2.Ludwig Boltzmann Institut für Klinische EndokrinologieViennaAustria